Search Results - "Mešić, Emir"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development by Noort, Martijn, Ruppert, Martijn, DeJongh, Joost, Marostica, Eleonora, Bosch, Rolien, Mešić, Emir, Snelder, Nelleke

    “…In pharmacometric modeling, it is often important to know whether the data is sufficiently rich to identify the parameters of a proposed model. While it may be…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Adenoviral vectors expressing siRNAs for discovery and validation of gene function by Arts, Gert-Jan, Langemeijer, Ellen, Tissingh, Rudi, Ma, Libin, Pavliska, Heidi, Dokic, Kristina, Dooijes, Richele, Mesić, Emir, Clasen, Remko, Michiels, Frits, van der Schueren, Jan, Lambrecht, Mark, Herman, Sofie, Brys, Reginald, Thys, Kim, Hoffmann, Marcel, Tomme, Peter, van Es, Helmuth

    Published in Genome research (01-10-2003)
    “…RNA interference is a powerful tool for studying gene function and for drug target discovery in diverse organisms and cell types. In mammalian systems, small…”
    Get full text
    Journal Article
  4. 4

    Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia by Mahar, Kelly M., Yang, Shuying, Mesic, Emir, Post, Teun M., Goulooze, Sebastiaan C.

    Published in Clinical pharmacokinetics (01-09-2024)
    “…Background and Objective Daprodustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the USA for treatment of…”
    Get full text
    Journal Article
  5. 5

    Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis by van den Berg, Paul, Ruppert, Martijn, Mesic, Emir, Snelder, Nelleke, Seelmann, Andreas, Heinig, Roland, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas

    Published in Clinical pharmacokinetics (01-03-2022)
    “…Background Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist that recently demonstrated efficacy in delaying chronic kidney disease…”
    Get full text
    Journal Article
  6. 6

    An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different Administration Routes by Reinecke, Isabel, Hofmann, Birte, Mesic, Emir, Drenth, Henk‐Jan, Garmann, Dirk

    Published in Journal of clinical pharmacology (01-12-2018)
    “…To compare the pharmacokinetics (PK) of the progestin levonorgestrel for various routes of administration, an integrated population PK analysis was performed…”
    Get full text
    Journal Article
  7. 7
  8. 8